1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 11
2.1 What is This Report About? 11
3 In Vitro Diagnostics In Norway 12
3.1 In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual, 2003-2017 12
3.2 In Vitro Diagnostics, Norway, Company share (2009-2010) 18
4 Clinical Chemistry In Norway 20
4.1 Clinical Chemistry Overall Revenue (2003-2017) 20
4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 24
4.1.2 Urine Analysis Analyzers Revenue (2003-2017) 28
4.2 Clinical Chemistry Distribution Share (2009-2010) 32
4.3 Clinical Chemistry, Norway, Company share (2009-2010) 33
5 Genetic Testing In Norway 35
5.1 Genetic Testing Overall Revenue (2003-2017) 35
5.2 Genetic Testing Distribution Share (2009-2010) 39
5.3 Genetic Testing, Norway, Company share (2009-2010) 40
6 Haematology In Norway 42
6.1 Haematology Overall Revenue (2003-2017) 42
6.1.1 Haematology Reagents Revenue (2003-2017) 46
6.1.2 Immunohaematology Revenue (2003-2017) 50
6.1.3 Haemostasis Revenue (2003-2017) 54
6.1.4 Haematology Rapid Tests Revenue (2003-2017) 58
6.1.5 Haematology Cell CountersRevenue (2003-2017) 62
6.2 Haematology Distribution Share (2009-2010) 66
6.3 Haematology, Norway, Company share (2009-2010) 67
7 Histology And Cytology In Norway 69
7.1 Histology And Cytology Overall Revenue (2003-2017) 69
7.2 Histology And Cytology Distribution Share (2009-2010) 73
7.3 Histology And Cytology, Norway, Company share (2009-2010) 74
8 Immuno Chemistry In Norway 76
8.1 Immuno Chemistry Overall Revenue (2003-2017) 76
8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 80
8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 84
8.1.3 Endocrinology Tests Revenue (2003-2017) 88
8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 92
8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 96
8.2 Immuno Chemistry Distribution Share (2009-2010) 100
8.3 Immuno Chemistry, Norway, Company share (2009-2010) 101
9 Infectious Immunology In Norway 103
9.1 Infectious Immunology Overall Revenue (2003-2017) 103
9.2 Infectious Immunology Distribution Share (2009-2010) 107
9.3 Infectious Immunology, Norway, Company share (2009-2010) 108
10 Microbiology Culture In Norway 110
10.1 Microbiology Culture Overall Revenue (2003-2017) 110
10.1.1 Microbiology Analyzers Revenue (2003-2017) 114
10.2 Microbiology Culture Distribution Share (2009-2010) 118
10.3 Microbiology Culture, Norway, Company share (2009-2010) 119
11 Overview of Key Companies in Norway In Vitro Diagnostics Market 121
11.1 F. Hoffmann-La Roche Ltd. 121
11.1.1 Company Overview 121
11.2 Siemens Healthcare 121
11.2.1 Company Overview 121
11.3 Abbott Laboratories 121
11.3.1 Company Overview 121
11.4 Ortho-Clinical Diagnostics Inc. 122
11.4.1 Company Overview 122
11.5 bioMerieux S.A. 122
11.5.1 Company Overview 122
11.6 Beckman Coulter, Inc. 122
11.6.1 Company Overview 122
11.7 Bio-Rad Laboratories, Inc. 123
11.7.1 Company Overview 123
11.8 Sysmex Corporation 123
11.8.1 Company Overview 123
11.9 Becton, Dickinson and Company 123
11.9.1 Company Overview 123
11.10 Phadia AB 123
11.10.1 Company Overview 123
11.11 Alere Inc. 124
11.11.1 Company Overview 124
11.12 DiaSorin S.p.A 124
11.12.1 Company Overview 124
11.13 Danaher Corporation 124
11.13.1 Company Overview 124
11.14 DIAGNOSTICA STAGO, Inc. 125
11.14.1 Company Overview 125
11.15 Thermo Fisher Scientific Inc. 125
11.15.1 Company Overview 125
11.16 PerkinElmer, Inc. 125
11.16.1 Company Overview 125
11.17 Qiagen N.V. 126
11.17.1 Company Overview 126
11.18 Gen-Probe Incorporated 126
11.18.1 Company Overview 126
11.19 Grifols, S.A. 126
11.19.1 Company Overview 126
11.20 HORIBA, Ltd. 127
11.20.1 Company Overview 127
11.21 Immucor, Inc. 128
11.21.1 Company Overview 128
11.22 Life Technologies Corporation 128
11.22.1 Company Overview 128
11.23 Hologic, Inc. 129
11.23.1 Company Overview 129
11.24 Cellestis Limited 129
11.24.1 Company Overview 129
12 Financial Deals Landscape 130
12.1 Partnerships 130
12.1.1 Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma 130
12.1.2 Biofortuna Enters Into Distribution Agreement With Abbott 131
12.1.3 NorDiag Enters Into Agreement With Precision System Science 133
13 Appendix 134
13.1 Global Markets Direct Research Methodology 134
13.2 Definitions of Markets Covered in the Report 135
13.2.1 In Vitro Diagnostics 135
13.3 Secondary Research 146
13.4 Primary Research 146
13.5 Models 147
13.6 Forecasts 147
13.7 Expert Panel Validation 147
13.8 Currency Conversion 148
13.9 Contact Us 148
13.10 Disclaimer 148
1.1 List of Tables
Table 1: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
2003-2017 13
Table 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 15
Table 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 17
Table 4: In Vitro Diagnostics, Norway, Company share by Revenue ($m), USD
Actual, 2009-2010 19
Table 5: Clinical Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 21
Table 6: Clinical Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 23
Table 7: Clinical Chemisty Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 25
Table 8: Clinical Chemisty Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 27
Table 9: Urine Analysis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 29
Table 10: Urine Analysis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 31
Table 11: Clinical Chemistry, Norway, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 32
Table 12: Clinical Chemistry, Norway, Company share by Revenue ($m), USD Actual
2009-2010 34
Table 13: Genetic Testing, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 36
Table 14: Genetic Testing, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 38
Table 15: Genetic Testing, Norway, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 39
Table 16: Genetic Testing, Norway, Company share by Revenue ($m), USD Actual
2009-2010 41
Table 17: Haematology, Norway, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 43
Table 18: Haematology, Norway, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 45
Table 19: Haematology Reagents, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 47
Table 20: Haematology Reagents, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 49
Table 21: Immunohaematology, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 51
Table 22: Immunohaematology, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 53
Table 23: Haemostasis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 55
Table 24: Haemostasis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 57
Table 25: Haematology Rapid Tests, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 59
Table 26: Haematology Rapid Tests, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 61
Table 27: Haematology Cell Counters, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 63
Table 28: Haematology Cell Counters, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 65
Table 29: Haematology, Norway, Distribution Share by Revenue ($m), USD Actual,
2009-2010 66
Table 30: Haematology, Norway, Company share by Revenue ($m), USD Actual
2009-2010 68
Table 31: Histology And Cytology, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 70
Table 32: Histology And Cytology, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 72
Table 33: Histology And Cytology, Norway, Distribution Share by Revenue ($m),
USD Actual, 2009-2010 73
Table 34: Histology And Cytology, Norway, Company share by Revenue ($m), USD
Actual 2009-2010 75
Table 35: Immuno Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 77
Table 36: Immuno Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 79
Table 37: Disease Specific Immunochemistry, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 81
Table 38: Disease Specific Immunochemistry, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 83
Table 39: Drugs of Abuse / Toxicology, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 85
Table 40: Drugs of Abuse / Toxicology, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 87
Table 41: Endocrinology Tests, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 89
Table 42: Endocrinology Tests, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 91
Table 43: Therapeutic Drug Monitoring, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 93
Table 44: Therapeutic Drug Monitoring, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 95
Table 45: Immunochemistry Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 97
Table 46: Immunochemistry Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 99
Table 47: Immuno Chemistry, Norway, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 100
Table 48: Immuno Chemistry, Norway, Company share by Revenue ($m), USD Actual
2009-2010 102
Table 49: Infectious Immunology, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 104
Table 50: Infectious Immunology, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 106
Table 51: Infectious Immunology, Norway, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 107
Table 52: Infectious Immunology, Norway, Company share by Revenue ($m), USD
Actual 2009-2010 109
Table 53: Microbiology Culture, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 111
Table 54: Microbiology Culture, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 113
Table 55: Microbiology Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 115
Table 56: Microbiology Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 117
Table 57: Microbiology Culture, Norway, Distribution Share by Revenue ($m), USD
Actual, 2009-2010 118
Table 58: Microbiology Culture, Norway, Company share by Revenue ($m), USD
Actual 2009-2010 120
Table 59: Skyline Diagnostics Enters Into Research Agreement With Clavis Pharma
130
Table 60: Biofortuna Enters Into Distribution Agreement With Abbott 131
Table 61: Trinity Biotech Enters Into Distribution Agreement With A. Menarini
Diagnostics 132
Table 62: NorDiag Enters Into Agreement With Precision System Science 133
Table 63: USD to Local Currency, Norway, Average Actual Rate 2003-2010 148
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
2003-2017 12
Figure 2: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
Historic, 2003-2010 14
Figure 3: In Vitro Diagnostics, Norway, Overall Revenue ($m), USD Actual,
Forecast, 2010-2017 16
Figure 4: In Vitro Diagnostics, Norway, Company share (%), 2010 18
Figure 5: Clinical Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 20
Figure 6: Clinical Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 22
Figure 7: Clinical Chemisty Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 24
Figure 8: Clinical Chemisty Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 26
Figure 9: Urine Analysis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 28
Figure 10: Urine Analysis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 30
Figure 11: Clinical Chemistry, Norway, Company share (%), 2010 33
Figure 12: Genetic Testing, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 35
Figure 13: Genetic Testing, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 37
Figure 14: Genetic Testing, Norway, Company share (%), 2010 40
Figure 15: Haematology, Norway, Revenue ($m), USD Actual by Segment, Historic,
2003-2010 42
Figure 16: Haematology, Norway, Revenue ($m), USD Actual by Segment, Forecast,
2010-2017 44
Figure 17: Haematology Reagents, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 46
Figure 18: Haematology Reagents, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 48
Figure 19: Immunohaematology, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 50
Figure 20: Immunohaematology, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 52
Figure 21: Haemostasis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 54
Figure 22: Haemostasis, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 56
Figure 23: Haematology Rapid Tests, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 58
Figure 24: Haematology Rapid Tests, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 60
Figure 25: Haematology Cell Counters, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 62
Figure 26: Haematology Cell Counters, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 64
Figure 27: Haematology, Norway, Company share (%), 2010 67
Figure 28: Histology And Cytology, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 69
Figure 29: Histology And Cytology, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 71
Figure 30: Histology And Cytology, Norway, Company share (%), 2010 74
Figure 31: Immuno Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 76
Figure 32: Immuno Chemistry, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 78
Figure 33: Disease Specific Immunochemistry, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 80
Figure 34: Disease Specific Immunochemistry, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 82
Figure 35: Drugs of Abuse / Toxicology, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 84
Figure 36: Drugs of Abuse / Toxicology, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 86
Figure 37: Endocrinology Tests, Norway, Revenue ($m), USD Actual by Sub-Segment,
Historic, 2003-2010 88
Figure 38: Endocrinology Tests, Norway, Revenue ($m), USD Actual by Sub-Segment,
Forecast, 2010-2017 90
Figure 39: Therapeutic Drug Monitoring, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 92
Figure 40: Therapeutic Drug Monitoring, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 94
Figure 41: Immunochemistry Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 96
Figure 42: Immunochemistry Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 98
Figure 43: Immuno Chemistry, Norway, Company share (%), 2010 101
Figure 44: Infectious Immunology, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 103
Figure 45: Infectious Immunology, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 105
Figure 46: Infectious Immunology, Norway, Company share (%), 2010 108
Figure 47: Microbiology Culture, Norway, Revenue ($m), USD Actual by Segment,
Historic, 2003-2010 110
Figure 48: Microbiology Culture, Norway, Revenue ($m), USD Actual by Segment,
Forecast, 2010-2017 112
Figure 49: Microbiology Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Historic, 2003-2010 114
Figure 50: Microbiology Analyzers, Norway, Revenue ($m), USD Actual by
Sub-Segment, Forecast, 2010-2017 116
Figure 51: Microbiology Culture, Norway, Company share (%), 2010 119
Figure 52: Global Markets Direct Methodology 134
Companies Menstion
F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
Ortho-Clinical Diagnostics Inc.
bioMerieux S.A.
Beckman Coulter, Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Becton, Dickinson and Company
Phadia AB
Alere Inc.
DiaSorin S.p.A
Danaher Corporation
DIAGNOSTICA STAGO, Inc.
Thermo Fisher Scientific Inc.
PerkinElmer, Inc.
Qiagen N.V.
Gen-Probe Incorporated
Grifols, S.A.
HORIBA, Ltd.
Immucor, Inc.
Life Technologies Corporation
Hologic, Inc.
Cellestis Limited
|
